Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: insulin glulisine Clear all
Completed Phase 3 Interventional

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

NCT00135941
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
insulin glargine, insulin glulisine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

NCT00911625
View directory record Official record
Conditions
Type 2 Diabetes, Renal Insufficiency
Interventions
0.5 units/kg daily insulin, 0.25 units/kg daily insulin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Chicago, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus

NCT00607087
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin glulisine, Insulin lispro, Insulin aspart
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

Diabetes in the Elderly: Prospective Study

NCT01131052
View directory record Official record
Conditions
Diabetes, Hyperglycemia
Interventions
Insulin Glargine, Insulin, Insulin glulisine
Drug
Lead sponsor
Guillermo Umpierrez
Other
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

NCT01194258
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Concord, California • Encino, California • Escondido, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 3 Interventional

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

NCT00115570
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Insulin glulisine, insulin lispro, insulin glargine, NPH insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 17 Years
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

Regular Insulin vs Rapid Insulin Delivered by V-Go

NCT03495908
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus
Interventions
VGo
Device
Lead sponsor
East Coast Institute for Research
Network
Eligibility
21 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Macon, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

NCT01621776
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Apidra, Humalog, Novolog
Drug
Lead sponsor
University of Florida
Other
Eligibility
9 Years to 14 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
DeLeon Springs, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 20, 2026, 1:45 PM EDT
Terminated Phase 2 Interventional Results available

Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

NCT02503501
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Interventions
Insulin glulisine, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

Comparative Trial Between 3 Types of Insulin Infusion Protocols

NCT00582309
View directory record Official record
Conditions
Hyperglycemia
Interventions
Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Chicago Heights, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Results available

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

NCT02432716
View directory record Official record
Conditions
Down Syndrome
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

NCT00979875
View directory record Official record
Conditions
Healthy
Interventions
Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Not applicable Interventional

Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)

NCT00708981
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Multifactorial Intervention
Other
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01848990
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro, Insulin aspart, Insulin glulisine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
39
States / cities
Concord, California • Encino, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Not applicable Interventional

Comparison of Apidra to Regular Insulin in Hospitalized Patients

NCT00528918
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Glulisine (Apidra)
Drug
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

Insulin Glargine "All to Target" Trial

NCT00384085
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glulisine, Insulin Glargine, Premixed Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 80 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

NCT02688933
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
99
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

NCT01792830
View directory record Official record
Conditions
Poor Glycemic Control
Interventions
Metformin, Glargine insulin, Glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

Glargine U300 Hospital Trial

NCT03013985
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glargine U300, Glargine U100, Glulisine Insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 2 Interventional

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes

NCT01662921
View directory record Official record
Conditions
Diabetes During Pregnancy
Interventions
NPH, Insulin LISPRO, Insulin glulisine
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 20, 2026, 1:45 PM EDT
Completed Phase 4 Interventional Results available

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

NCT00590044
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
insulin glargine+ glulisine, NPH + Regular insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 20, 2026, 1:45 PM EDT
Withdrawn Phase 3 Interventional

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

NCT00943709
View directory record Official record
Conditions
Hyperglycemia, Leukemia
Interventions
insulin glargine recombinant, therapeutic insulin
Biological · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Sep 20, 2026, 1:45 PM EDT
Terminated Phase 4 Interventional Results available

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

NCT00283049
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Insulin Glulisine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Sep 20, 2026, 1:45 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

NCT03260868
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Sep 20, 2026, 1:45 PM EDT